Anjum Zaki
Overview
Explore the profile of Anjum Zaki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
28
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cole C, Morelli M, Fantini M, Miettinen M, Fetsch P, Peer C, et al.
J Exp Clin Cancer Res
. 2023 Apr;
42(1):102.
PMID: 37101182
No abstract available.
2.
Cole C, Morelli M, Fantini M, Miettinen M, Fetsch P, Peer C, et al.
J Exp Clin Cancer Res
. 2023 Mar;
42(1):76.
PMID: 36991390
Background: NEO201 is a humanized IgG1 monoclonal antibody (mAb) generated against tumor-associated antigens from patients with colorectal cancer. NEO-201 binds to core 1 or extended core 1 O-glycans expressed by...
3.
Huffman B, Basu Mallick A, Horick N, Wang-Gillam A, Hosein P, Morse M, et al.
JAMA Netw Open
. 2023 Jan;
6(1):e2249720.
PMID: 36602796
Importance: Treatment options are limited for patients with advanced pancreatic ductal adenocarcinoma (PDAC) beyond first-line 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX), with such individuals commonly being treated with gemcitabine and...
4.
Tsang K, Fantini M, Zaki A, Mavroukakis S, Morelli M, Annunziata C, et al.
Cancers (Basel)
. 2022 Oct;
14(20).
PMID: 36291783
Truncated O-glycans expressed in cancer cells support tumor progression, and they may serve as potential targets to improve the monitoring and treatment of cancers. Previously, we reported that NEO-201 binds...
5.
Tsang K, Fantini M, Mavroukakis S, Zaki A, Annunziata C, Arlen P
Cancers (Basel)
. 2022 Jul;
14(13).
PMID: 35804808
NEO-201 is an IgG1 humanized monoclonal antibody (mAb) that binds to tumor-associated variants of carcinoembryonic antigen-related cell adhesion molecule (CEACAM)-5 and CEACAM-6. NEO-201 reacts to colon, ovarian, pancreatic, non-small cell...
6.
Kim R, Azad N, Morse M, Poplin E, Mahipal A, Tan Jr B, et al.
Clin Cancer Res
. 2020 Apr;
26(14):3557-3564.
PMID: 32303539
Purpose: Patients with metastatic colorectal cancer refractory to chemotherapy have limited treatment options. Ensituximab (NEO-102) is a novel chimeric mAb targeting a variant of with specificity to colorectal cancer. Patients...